Abstract:BACKGROUND:Outcomes are poor for patients with previously treated, advanced or metastatic non-small-cell lung cancer (NSCLC). The anti-programmed death ligand 1 (PD-L1) antibody atezolizumab is clinically active against cancer, including NSCLC, especially cancers expressing PD-L1 on tumour cells, tumour-infiltrating immune cells, or both. We assessed efficacy and safety of atezolizumab versus docetaxel in previously treated NSCLC, analysed by PD-L1 expression levels on tumour cells and tumour-infiltrating immune cells and in the intention-to-treat population.METHODS:In this open-label, phase 2 randomised controlled trial, patients with NSCLC who progressed on post-platinum chemotherapy were recruited in 61 academic medical centres and community oncology practices across 13 countries in Europe and North America. Key inclusion criteria were Eastern Cooperative Oncology Group performance status 0 or 1, measurable disease by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1), and adequate haematological and end-organ function. Patients were stratified by PD-L1 tumour-infiltrating immune cell status, histology, and previous lines of therapy, and randomly assigned (1:1) by permuted block randomisation (with a block size of four) using an interactive voice or web system to receive intravenous atezolizumab 1200 mg or docetaxel 75 mg/m(2) once every 3 weeks. Baseline PD-L1 expression was scored by immunohistochemistry in tumour cells (as percentage of PD-L1-expressing tumour cells TC3≥50%, TC2≥5% and <50%, TC1≥1% and <5%, and TC0<1%) and tumour-infiltrating immune cells (as percentage of tumour area: IC3≥10%, IC2≥5% and <10%, IC1≥1% and <5%, and IC0<1%). The primary endpoint was overall survival in the intention-to-treat population and PD-L1 subgroups at 173 deaths. Biomarkers were assessed in an exploratory analysis. We assessed safety in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01903993.FINDINGS:Patients were enrolled between Aug 5, 2013, and March 31, 2014. 144 patients were randomly allocated to the atezolizumab group, and 143 to the docetaxel group. 142 patients received at least one dose of atezolizumab and 135 received docetaxel. Overall survival in the intention-to-treat population was 12·6 months (95% CI 9·7-16·4) for atezolizumab versus 9·7 months (8·6-12·0) for docetaxel (hazard ratio [HR] 0·73 [95% CI 0·53-0·99]; p=0·04). Increasing improvement in overall survival was associated with increasing PD-L1 expression (TC3 or IC3 HR 0·49 [0·22-1·07; p=0·068], TC2/3 or IC2/3 HR 0·54 [0·33-0·89; p=0·014], TC1/2/3 or IC1/2/3 HR 0·59 [0·40-0·85; p=0·005], TC0 and IC0 HR 1·04 [0·62-1·75; p=0·871]). In our exploratory analysis, patients with pre-existing immunity, defined by high T-effector-interferon-γ-associated gene expression, had improved overall survival with atezolizumab. 11 (8%) patients in the atezolizumab group discontinued because of adverse events versus 30 (22%) patients in the docetaxel group. 16 (11%) patients in the atezolizumab group versus 52 (39%) patients in the docetaxel group had treatment-related grade 3-4 adverse events, and one (<1%) patient in the atezolizumab group versus three (2%) patients in the docetaxel group died from a treatment-related adverse event.INTERPRETATION:Atezolizumab significantly improved survival compared with docetaxel in patients with previously treated NSCLC. Improvement correlated with PD-L1 immunohistochemistry expression on tumour cells and tumour-infiltrating immune cells, suggesting that PD-L1 expression is predictive for atezolizumab benefit. Atezolizumab was well tolerated, with a safety profile distinct from chemotherapy.FUNDING:F Hoffmann-La Roche/Genentech Inc.

Brief Report: Phase II clinical trial of atezolizumab in advanced non-small cell lung cancer patients previously treated with PD-1-directed therapy

Data from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

P3.02c-050 IMpower010: Phase III Study of Atezolizumab Vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC

PS01.55: IMpower010: Phase III Study of Atezolizumab Vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC: Topic: Medical Oncology.

A Phase III Trial to Compare Atezolizumab (atezo) Vs Best Supportive Care (BSC) Following Adjuvant Chemotherapy in Patients (pts) with Completely Resected NSCLC: IMpower010.

Adjuvant Atezolizumab after Adjuvant Chemotherapy in Resected Stage IB–IIIA Non-Small-cell Lung Cancer (impower010): a Randomised, Multicentre, Open-Label, Phase 3 Trial

Long-term Survival Follow-Up of Atezolizumab in Combination with Platinum-Based Doublet Chemotherapy in Patients with Advanced Non-Small-cell Lung Cancer

Phase Ib Study of Sintilimab in Combination with Chemotherapy for 1L Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC

Clinical outcomes of atezolizumab versus standard-of-care docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

Atezolizumab Versus Docetaxel for Patients with Previously Treated Non-Small-cell Lung Cancer (POPLAR): a Multicentre, Open-Label, Phase 2 Randomised Controlled Trial.

Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.

P1.04-02 Efficacy and Safety of Sintilimab with Anlotinib As First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

TS01.03 Efficacy and Safety Data from a Phase 1/2 Trial of Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)

Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Results From a Phase 1b Trial

Safety and efficacy of sintilimab in combination with SBRT and LDRT in PD-L1 positive treatment naïve-stage IV non-small cell lung cancer: A phase I study (IHC study).

Safety and efficacy of sintilimab in combination with SBRT and LDRT in PD-L1 positive treatment naive-stage IV non-small cell lung cancer: A phase I study (IHC study).